Two months after officially escaping the Banco Master scandal, following the entry of the asset manager Alaska into its shareholding structure, the Brazilian pharmaceutical company Biomm , the only national manufacturer of insulin glargine (an analogue of human insulin), plans a significant jump in its financial results this year.
In a material fact disclosed late Tuesday afternoon, June 9, the company reported guidance of between R$ 90 million and R$ 100 million in EBITDA in relation to its projected performance for 2026.
The plan is based on the ramp-up of the factory in Nova Lima, Minas Gerais, inaugurated in 2024, and on existing partnership agreements for the productive development (PDP) of glargine with Biomanguinhos and Fiocruz, and of human insulin with the Ezequiel Dias Foundation (Funed).
There is also a plan to expand the Glargilin brand, an injectable medication for the treatment of type 1 and type 2 diabetes, in the private pharmaceutical market in Brazil.
If the company manages to confirm this guidance by the end of the fiscal year, it will have achieved significant growth compared to last year. In its fourth-quarter earnings report, the company reported EBITDA of R$ 3.3 million, compared to a negative figure of R$ 69.3 million in 2024.
This was the first time the company did not end a fiscal year in the red. Taking into account last year's scenario and the company's outlook, Biomm forecasts growth of approximately 3,000% over 12 months.
"The projections disclosed in this document are estimates that reflect the current expectations of management and do not constitute, guarantee, or predict results. Such projections depend on volatile factors and conditions beyond the Company's control," says the document, signed by Marcelo Sáfadi Álvares, CFO and director of investor relations at Biomm.
The very act of disclosing the guidance represents a significant shift in the company's stance, as it had not previously revealed this type of information to the market. Approval for this disclosure was granted at the company's last board meeting, held on May 28th.
When the scandal involving Daniel Vorcaro 's bank broke, which was liquidated by the Central Bank (BC) in November 2025, the market's attention turned to the pharmaceutical company, precisely because of the presence of the problematic partner , who held a significant stake of 25.86%.
Vorcaro's presence was through the Cartago Investment Fund. A document produced by the Central Bank in the past, which NeoFeed had access to, confirmed that Cartago was part of the Master conglomerate, along with 39 other companies and investment funds.
In April of this year, Alaska acquired a 26.15% stake in the company. The asset manager acquired the majority of the shares from Banco de Brasília (BRB), which had retained the stake held by Cartago, which was also liquidated. The asset manager also purchased the shares of Cedro Participações, which held 7.8%.
The company was founded in 2001 by Walfrido dos Mares Guia, who was Minister of Tourism during Luiz Inácio Lula da Silva's first term, between 2003 and 2006. He holds an 8.24% stake.
BTGP Gestão holds 12.2%, followed by TMG/IBR with 7.25%. The National Bank for Economic and Social Development (BNDES), through BNDESPar, holds 5.12%.
In the midst of the process involving a possible change in corporate leadership, Biomm changed its CEO. Guilherme Maradei took over on January 1st of this year, following a transition with executive Heraldo Marchezini, who had been in the position since 2013.
At the time, the company stated that the replacement had been under discussion for some time, and that the process of choosing Marchezini's successor had taken at least six months.
In the first quarter of this year, the pharmaceutical company reported net revenue of R$ 92.4 million, 133.5% higher than the result for the first three months of 2025, which was R$ 39.6 million. Net profit was R$ 9.7 million, reversing a loss of R$ 11.7 million in the same period last year.
Before the scandal broke, Biomm had already revealed its intention to enter the market for slimming pens in Brazil, as it operates, in a way, in a related sector. To this end, it signed a contract in 2024 with the Indian company Biocon to license and distribute the similar product Ozempic in the country. The company is currently awaiting registration from the National Health Surveillance Agency (Anvisa).
In the accumulated total for 2026, BIOM3 shares on the B3 stock exchange have registered a depreciation of 5.6%. Over 12 months, the drop is 25%. Biomm's market value is R$ 917 million.
